VR Logo

Astria Therapeutics Inc. (ATXS) download report


Healthcare | Biotechnology & Pharma Research

Astria Therapeutics Inc. (ATXS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.

IPO Date: 25-Jun-2015

Co-Founder, CEO, Pres & Director: Ms. Jill C. Milne Ph.D.

Chief Financial Officer: Mr. Noah Clauser CPA

Listing: NASDAQ: ATXS

Country: United States

Headquarters: Boston, MA

Website: https://www.astriatx.com

Key Facts

Market cap: $39.31 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-64.59 Mln

Cash: $112.82 Mln

Total Debt: $0.18 Mln

Insider's Holding: 2.06%

Liquidity: Low

52 Week range: $2.36 - 14.04

Shares outstanding: 13,017,000

5 Years Aggregate:

  • CFO: $-139.51 Mln
  • EBITDA: $-310.93 Mln
  • Net Profit: $-311.74 Mln

Stock Performance

Time Period Astria Therapeutics (ATXS) S&P BSE Sensex S&P Small-Cap 600
YTD-46.01-8.74-17.05
1 month-8.06-2.01-4.75
3 months-57.83-7.32-12.64
1 Year-77.440.45-16.28
3 Years-60.0610.328.01
5 Years-48.7411.296.36
10 Years--12.1410.55
As on 27-Jun-2022
Year Astria Therapeutics (ATXS) S&P Small-Cap 600 S&P BSE Sensex
2021-58.0225.2721.99
2020-63.799.5715.75
201935.2420.8614.38
2018-70.47-9.705.87
2017-58.7311.7327.91
2016-54.4824.741.95